Drug intelligence / Profile preview

Alergoliber

Development stage: Unknown
Lead developer: Atco Pharma
Modality: Small Molecules
Administration: Oral

Overview

Alergoliber is an antihistamine medication developed and marketed by Atco Pharma for the treatment of allergic conditions. Its active ingredient is rupatadine fumarate, a second-generation antihistamine that uniquely exhibits dual activity as both a selective histamine H1 receptor antagonist and a platelet-activating factor (PAF) antagonist. This dual mechanism provides relief from symptoms associated with allergic rhinitis and chronic urticaria. It is available in tablet and oral syrup formulations and is approved for use in adults and children over 12 years of age.

Brand names: Alergoliber
Other names: rupatadine fumaraterupatadine

Targets

PTAFR (Platelet-activating factor receptor)HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on Alergoliber.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alergoliber.

Explore the full profile